Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02323230 is registered in ClinicalTrials.gov with ImmunoVaccine Technologies, Inc. (IMV Inc.) as lead sponsor.

NCT NCT02323230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02323230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2015
Completion date
February 28, 2018
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma